AI-powered Chatbot vs. Human Counselors in Smoking Cessation
Launched by BEIJING NORMAL UNIVERSITY · Aug 22, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to compare the help provided by an AI-powered chatbot to that of human counselors for people trying to quit smoking. The goal is to see if the chatbot can be effective and helpful for smokers in the community. If you're a smoker aged 18 or older, live in Zhuhai for at least the next six months, and use a smartphone with a WeChat account, you might be eligible to participate. However, if you have trouble communicating or are currently enrolled in other smoking cessation programs, you won't be able to join.
Participants in this study can expect to receive support for quitting smoking either from the chatbot or a human counselor. It's a great opportunity to explore new ways to get help in your journey to stop smoking. The trial is not yet recruiting, so if you’re interested, keep an eye out for updates!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. aged 18 and above, reside in Zhuhai for the next 6 months;
- • 2. smoke at least 1 cigarette or use e-cigarettes daily;
- • 3. Having a smartphone and a WeChat account, being able to use WeChat skillfully.
- Exclusion Criteria:
- • 1. Smokers who have communication barrier (either physically or cognitively);
- • 2. Smokers who are currently participating in other SC programmes or services
About Beijing Normal University
Beijing Normal University is a prestigious academic institution in China, renowned for its commitment to advancing research and education across various disciplines, including the fields of health and life sciences. As a clinical trial sponsor, the university leverages its extensive expertise, state-of-the-art facilities, and collaborative networks to facilitate innovative research initiatives. By fostering partnerships with healthcare institutions and industry stakeholders, Beijing Normal University aims to contribute to the development of cutting-edge therapeutic solutions, enhance patient outcomes, and promote public health through rigorous clinical investigations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhuhai, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported